Squarepoint
FBRX icon

Squarepoint’s Forte Biosciences FBRX Stock Holding History

Squarepoint’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$538K Buy
+20,755
New +$598K ﹤0.01% 3282
2022
Q1 		– Sell
-525
Closed -$28K – 3052
2021
Q4 		$28K Buy
+525
New +$35.3K ﹤0.01% 3074
2021
Q2 		– Sell
-463
Closed -$397K – 3370
2021
Q1 		$397K Buy
+463
New +$379K ﹤0.01% 2197
2019
Q2 		– Sell
-34
Closed -$140K – 2461
2019
Q1 		$140K Sell
34
-62
-65% -$240K ﹤0.01% 2001
2018
Q4 		$295K Buy
+96
New +$413K ﹤0.01% 1519

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Squarepoint's FBRX Position: Q1 2026 in Review

Squarepoint opened a new position in Forte Biosciences (FBRX) in Q1 2026: 20,755 shares worth $538K. The stake represents ﹤0.01% of the portfolio and ranks #3282 among its holdings. This is a return to the name: Squarepoint previously reported a position in FBRX as recently as Q4 2021.

Squarepoint first reported a position in FBRX in Q4 2018 and has held it in 5 quarters since. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Squarepoint held 20,755 shares of Forte Biosciences worth $538K as of Q1 2026.
  • Forte Biosciences was a new Squarepoint position in Q1 2026.
  • Forte Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3282 holding.
  • Squarepoint first reported a position in Forte Biosciences in Q4 2018 and has held it in 5 quarters since.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.